9.86
-0.3(-2.95%)
Currency In USD
| Previous Close | 10.16 |
| Open | 9.96 |
| Day High | 10.05 |
| Day Low | 9.45 |
| 52-Week High | 19.73 |
| 52-Week Low | 5.41 |
| Volume | 1.55M |
| Average Volume | 1.93M |
| Market Cap | 857.99M |
| PE | -3.98 |
| EPS | -2.48 |
| Moving Average 50 Days | 9.2 |
| Moving Average 200 Days | 7.36 |
| Change | -0.3 |
If you invested $1000 in Kura Oncology, Inc. (KURA) 10 years ago, it would be worth $1,221.81 as of November 08, 2025 at a share price of $9.86. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $261.05 as of November 08, 2025 at a share price of $9.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
GlobeNewswire Inc.
Nov 03, 2025 9:02 PM GMT
– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials –SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to re
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:14 PM GMT
– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use – SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE
Kura Oncology to Report Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Oct 28, 2025 8:01 PM GMT
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third